labetalol has been researched along with Acute Disease in 32 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Food and Drug Administration (FDA)-recommended doses of labetalol and nicardipine for hypertension (HTN) management in a subset of patients with renal dysfunction (RD)." | 9.19 | The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine? ( Baumann, BM; Borczuk, P; Cannon, CM; Chandra, A; Cline, DM; Diercks, DB; Hiestand, B; Hsu, A; Jois-Bilowich, P; Kaminski, B; Levy, P; Nowak, RM; Peacock, WF; Schrock, JW; Soto-Ruiz, KM; Varon, J, 2014) |
| "We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol." | 9.15 | Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. ( Baggio, MR; Berezowski, AT; Calderon, AC; Cavalli, RC; Duarte, G; Marcolin, AC; Martins, WP, 2011) |
| "The aim of this study was to evaluate the use of as-needed (PRN) labetalol and hydralazine [intravenous (IV) or oral] in hospitalized medicine patients for the treatment of severe asymptomatic hypertension and to examine the potential negative outcomes associated with their use." | 7.88 | Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients. ( Gaynor, MF; Vondracek, S; Wright, GC, 2018) |
| "Evaluate the ease of use and tolerability of labetalol (L) and nicardipine (N) for hypertension management in patients with acute stroke." | 7.74 | A comparison of nicardipine and labetalol for acute hypertension management following stroke. ( Coplin, WM; Janisse, J; Liu-Deryke, X; Norris, G; Parker, D; Rhoney, DH, 2008) |
| " This patient with Marfan syndrome whose case is reported herein presented with chest pain, hypertensive crisis, and aortic insufficiency; labetalol was used successfully to treat the acute hypertensive crisis and magnetic resonance imaging (MRI) was used to differentiate between aortic dissection and an expanding aortic aneurysm." | 7.68 | Labetalol and MRI as initial medical and diagnostic modalities in a marfanoid patient with expanding ascending aortic aneurysm. ( Baciewicz, FA; Grubb, B; Laden, N, 1990) |
| "1 The role of labetalol in managing acute myocardial infarction is reviewed." | 7.66 | Role of labetalol in acute myocardial infarction. ( Chamberlain, DA; Fowler, MB; Jaggarao, NS; Timmis, AD; Vincent, R, 1982) |
| " Food and Drug Administration (FDA)-recommended doses of labetalol and nicardipine for hypertension (HTN) management in a subset of patients with renal dysfunction (RD)." | 5.19 | The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine? ( Baumann, BM; Borczuk, P; Cannon, CM; Chandra, A; Cline, DM; Diercks, DB; Hiestand, B; Hsu, A; Jois-Bilowich, P; Kaminski, B; Levy, P; Nowak, RM; Peacock, WF; Schrock, JW; Soto-Ruiz, KM; Varon, J, 2014) |
| "We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol." | 5.15 | Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. ( Baggio, MR; Berezowski, AT; Calderon, AC; Cavalli, RC; Duarte, G; Marcolin, AC; Martins, WP, 2011) |
| "Our purpose was to compare the safety and efficacy of food and drug administration (FDA) recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension." | 5.15 | CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. ( Baumann, BM; Borczuk, P; Cannon, CM; Chandra, A; Cline, DM; Diercks, D; Hiestand, B; Hsu, A; Jois-Bilowich, P; Kaminski, B; Levy, P; Nowak, RM; Peacock, WF; Schrock, JW; Varon, J, 2011) |
| "Labetalol and lisinopril are effective antihypertensive drugs in acute stroke that do not increase serious adverse events." | 5.14 | Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. ( Chernova, J; Ford, GA; Jagger, C; James, M; Mistri, A; Potter, JF; Robinson, TG, 2009) |
| "The aim of this study was to evaluate the use of as-needed (PRN) labetalol and hydralazine [intravenous (IV) or oral] in hospitalized medicine patients for the treatment of severe asymptomatic hypertension and to examine the potential negative outcomes associated with their use." | 3.88 | Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients. ( Gaynor, MF; Vondracek, S; Wright, GC, 2018) |
| "Evaluate the ease of use and tolerability of labetalol (L) and nicardipine (N) for hypertension management in patients with acute stroke." | 3.74 | A comparison of nicardipine and labetalol for acute hypertension management following stroke. ( Coplin, WM; Janisse, J; Liu-Deryke, X; Norris, G; Parker, D; Rhoney, DH, 2008) |
| " This patient with Marfan syndrome whose case is reported herein presented with chest pain, hypertensive crisis, and aortic insufficiency; labetalol was used successfully to treat the acute hypertensive crisis and magnetic resonance imaging (MRI) was used to differentiate between aortic dissection and an expanding aortic aneurysm." | 3.68 | Labetalol and MRI as initial medical and diagnostic modalities in a marfanoid patient with expanding ascending aortic aneurysm. ( Baciewicz, FA; Grubb, B; Laden, N, 1990) |
| "1 The role of labetalol in managing acute myocardial infarction is reviewed." | 3.66 | Role of labetalol in acute myocardial infarction. ( Chamberlain, DA; Fowler, MB; Jaggarao, NS; Timmis, AD; Vincent, R, 1982) |
| "This is a substudy of the multicenter safety and efficacy Evaluation of intravenous Cardene (nicardipine) and Labetalol Use in the Emergency department (CLUE) trial that randomized patients to Food and Drug Administration-recommended intravenous dosing of nicardipine or labetalol to reach a physician predefined systolic BP (SBP) and target range (TR) of ±20 mm Hg within 30 minutes." | 2.79 | Impact of initial blood pressure on antihypertensive response in patients with acute hypertension. ( Farias, S; Gonzalez, M; Levy, PD; Peacock, WF, 2014) |
| "In the case of hypertensive encephalopathy, the lowering of blood pressure is therapeutic as well as diagnostic." | 2.43 | [Antihypertensive management in acute cerebral stroke]. ( Ziliene, V, 2005) |
| "We present an unusual case of spinal cord ischemia from an acute type B intramural hematoma that was successfully treated with blood pressure elevation and drainage of cerebral spinal fluid." | 1.39 | Acute intramural hematoma of the aorta complicated by spinal cord ischemia. ( Cassiere, HA; Liang, D; Yu, PJ, 2013) |
| "This study used an animal model of acute pancreatitis induced by intravenous caeruleint (10 micrograms/kg/h for up to six hours), which does not entail either haemorrhage or significant necrosis of the pancreas." | 1.29 | Vasoactive mediators and the progression from oedematous to necrotising experimental acute pancreatitis. ( Adler, G; Gress, TM; Lerch, MM; Pfaff, D; Turi, S; Weidenbach, H, 1995) |
| "The episodes of acute secondary erythermalgia were transient in all and did not recur after a mean follow up period of 1." | 1.29 | Acute secondary erythermalgia and hypertension in children. Erythermalgia Multidisciplinary Study Group. ( Drenth, JP; Michiels, JJ; Ozsoylu, S, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.38) | 18.7374 |
| 1990's | 6 (18.75) | 18.2507 |
| 2000's | 11 (34.38) | 29.6817 |
| 2010's | 11 (34.38) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, J | 1 |
| McNaughton, C | 1 |
| Joyce, K | 1 |
| Binz, S | 1 |
| Levy, P | 3 |
| Gaynor, MF | 1 |
| Wright, GC | 1 |
| Vondracek, S | 1 |
| Yu, PJ | 1 |
| Cassiere, HA | 1 |
| Liang, D | 1 |
| Farias, S | 1 |
| Peacock, WF | 4 |
| Gonzalez, M | 1 |
| Levy, PD | 2 |
| Varon, J | 3 |
| Soto-Ruiz, KM | 1 |
| Baumann, BM | 2 |
| Borczuk, P | 2 |
| Cannon, CM | 2 |
| Chandra, A | 2 |
| Cline, DM | 2 |
| Diercks, DB | 1 |
| Hiestand, B | 2 |
| Hsu, A | 2 |
| Jois-Bilowich, P | 2 |
| Kaminski, B | 2 |
| Nowak, RM | 2 |
| Schrock, JW | 2 |
| Martin-Schild, S | 1 |
| Potter, JF | 1 |
| Robinson, TG | 1 |
| Ford, GA | 1 |
| Mistri, A | 1 |
| James, M | 1 |
| Chernova, J | 1 |
| Jagger, C | 1 |
| Liu, X | 1 |
| Yang, le J | 1 |
| Fan, SJ | 1 |
| Jiang, H | 1 |
| Pan, F | 1 |
| Baggio, MR | 1 |
| Martins, WP | 1 |
| Calderon, AC | 1 |
| Berezowski, AT | 1 |
| Marcolin, AC | 1 |
| Duarte, G | 1 |
| Cavalli, RC | 1 |
| Sebastian, J | 1 |
| Emery, D | 1 |
| Kotylak, T | 1 |
| Butcher, KS | 1 |
| Diercks, D | 1 |
| Hilleman, DE | 1 |
| Rhoney, DH | 2 |
| Marik, PE | 1 |
| Rivera, R | 1 |
| Odunukan, OW | 1 |
| Abudiab, MM | 1 |
| Sinak, LJ | 1 |
| Recordati, G | 1 |
| Zorzoli, F | 1 |
| Pontara, O | 1 |
| Turolo, L | 1 |
| Zanchetti, A | 1 |
| Lindsberg, PJ | 1 |
| Soinne, L | 1 |
| Roine, RO | 1 |
| Salonen, O | 1 |
| Tatlisumak, T | 1 |
| Kallela, M | 1 |
| Häppölä, O | 1 |
| Tiainen, M | 1 |
| Haapaniemi, E | 1 |
| Kuisma, M | 1 |
| Kaste, M | 1 |
| Ziliene, V | 1 |
| Semplicini, A | 1 |
| Calò, L | 1 |
| Donaghy, S | 1 |
| Liu-Deryke, X | 1 |
| Janisse, J | 1 |
| Coplin, WM | 1 |
| Parker, D | 1 |
| Norris, G | 1 |
| Koch, S | 1 |
| Romano, JG | 1 |
| Forteza, AM | 1 |
| Otero, CM | 1 |
| Rabinstein, AA | 1 |
| Timmis, AD | 1 |
| Fowler, MB | 1 |
| Jaggarao, NS | 1 |
| Vincent, R | 1 |
| Chamberlain, DA | 1 |
| Weidenbach, H | 1 |
| Lerch, MM | 1 |
| Gress, TM | 1 |
| Pfaff, D | 1 |
| Turi, S | 1 |
| Adler, G | 1 |
| O'Connor, B | 1 |
| Luntley, JB | 1 |
| Amar, D | 1 |
| Shamoon, H | 1 |
| Lazar, EJ | 1 |
| Frishman, WH | 1 |
| Drenth, JP | 1 |
| Michiels, JJ | 1 |
| Ozsoylu, S | 1 |
| Fagan, SC | 1 |
| Bowes, MP | 1 |
| Lyden, PD | 1 |
| Zivin, JA | 1 |
| Powers, WJ | 1 |
| Zazulia, AR | 1 |
| Videen, TO | 1 |
| Adams, RE | 1 |
| Yundt, KD | 1 |
| Aiyagari, V | 1 |
| Grubb, RL | 1 |
| Diringer, MN | 1 |
| Spierings, EL | 1 |
| Ronne-Rasmussen, JO | 1 |
| Andersen, GS | 1 |
| Jensen, NB | 1 |
| Andersson, E | 1 |
| Laden, N | 1 |
| Baciewicz, FA | 1 |
| Grubb, B | 1 |
| Eisele, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IV, Randomized Trial to Determine the Efficacy and Safety of Cardene Intravenous (I.V.) Versus Labetalol for Management of Hypertensive Emergencies in the Emergency Department Setting[NCT00765648] | Phase 4 | 226 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655] | 500 participants (Anticipated) | Interventional | 2017-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Calculated as the mean (± standard deviation) number of titrations over 30 minutes for each treatment group (NCT00765648)
Timeframe: 30 minutes
| Intervention | number of titrations (Mean) |
|---|---|
| Nicardipine | 2.2 |
| Labetalol | 1.3 |
Median number of hours from hospital admission until Emergency Department(ED)disposition (NCT00765648)
Timeframe: 6 hours
| Intervention | hours (Median) |
|---|---|
| Nicardipine | 4.6 |
| Labetalol | 4.6 |
Percentage of subjects achieving a pre-defined target systolic blood pressure (BP) range defined as a systolic blood pressure that is within +/- 20 mmHg of the target as established by the investigator. (NCT00765648)
Timeframe: 30 minutes after initiation of therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Nicardipine | 91.7 |
| Labetalol | 82.5 |
The percent of subjects requiring the use of intravenous rescue medications (NCT00765648)
Timeframe: 6 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Nicardipine | 15.5 |
| Labetalol | 22.4 |
The median transition time (in hours) to oral medication (NCT00765648)
Timeframe: 6 hours
| Intervention | hours (Median) |
|---|---|
| Nicardipine | 4.9 |
| Labetalol | 6.4 |
Treatment failure is defined as admission to the hospital or observation unit for BP management (NCT00765648)
Timeframe: 6 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Nicardipine | 43.1 |
| Labetalol | 37.4 |
4 reviews available for labetalol and Acute Disease
| Article | Year |
|---|---|
Hypertension Management in Emergency Departments.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2020 |
A systematic review of nicardipine vs labetalol for the management of hypertensive crises.
Topics: Acute Disease; Antihypertensive Agents; Humans; Hypertension; Labetalol; Nicardipine | 2012 |
Hypertensive emergencies: an update.
Topics: Acute Disease; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Critical Care; | 2011 |
[Antihypertensive management in acute cerebral stroke].
Topics: Acute Disease; Adult; Antihypertensive Agents; Brain Injuries; Cerebrovascular Circulation; Emergenc | 2005 |
9 trials available for labetalol and Acute Disease
| Article | Year |
|---|---|
Impact of initial blood pressure on antihypertensive response in patients with acute hypertension.
Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Creatinine; Emergency Service, Hospital; Hum | 2014 |
The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine?
Topics: Acute Disease; Antihypertensive Agents; Comorbidity; Double-Blind Method; Female; Humans; Hypertensi | 2014 |
Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial.
Topics: Acute Disease; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Humans; H | 2009 |
Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial.
Topics: Acute Disease; Adult; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension; Labetalol; | 2011 |
CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department.
Topics: Acute Disease; Adult; Aged; Antihypertensive Agents; Blood Pressure; Emergency Service, Hospital; Fe | 2011 |
Community-based thrombolytic therapy of acute ischemic stroke in Helsinki.
Topics: Academic Medical Centers; Acute Disease; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bl | 2003 |
Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety.
Topics: Acute Disease; Aged; Antihypertensive Agents; Blood Pressure; Brain Edema; Feasibility Studies; Fema | 2008 |
Acute hyperglycaemic effect of anaesthetic induction with thiopentone.
Topics: Acute Disease; Anesthesia, Intravenous; Blood Glucose; Epinephrine; Female; Glucagon; Humans; Hyperg | 1993 |
Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage.
Topics: Acute Disease; Adult; Aged; Antihypertensive Agents; Blood Pressure; Cerebral Hemorrhage; Cerebrovas | 2001 |
19 other studies available for labetalol and Acute Disease
| Article | Year |
|---|---|
Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adrenergic Antagonists; Adult; Age | 2018 |
Acute intramural hematoma of the aorta complicated by spinal cord ischemia.
Topics: Acute Disease; Administration, Oral; Adult; Antihypertensive Agents; Aortic Diseases; Blood Pressure | 2013 |
Blood pressure in acute stroke: lower it or let the CHHIPS fall where they will.
Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Humans; Hypertensi | 2009 |
Swimming exercise effects on the expression of HSP70 and iNOS in hippocampus and prefrontal cortex in combined stress.
Topics: Acute Disease; Adrenergic Antagonists; Animals; Chronic Disease; Corticosterone; Hippocampus; HSP70 | 2010 |
Cerebral blood flow measurement following extreme blood pressure reduction in an acute intracerebral hemorrhage patient.
Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Cerebral Hemorrhage; Cerebrovascular Circula | 2011 |
48-year-old man with cough and leg swelling.
Topics: Acute Disease; Antihypertensive Agents; Cerebrovascular Circulation; Cough; Dyspnea; Echocardiograph | 2012 |
Factors influencing acute ischaemia-induced renal hypertension in rats.
Topics: Acute Disease; Animals; Antihypertensive Agents; Biphenyl Compounds; Diuresis; Hematocrit; Hypertens | 2002 |
Administering antihypertensive drugs after acute ischemic stroke: timing is everything.
Topics: Acute Disease; Antihypertensive Agents; Brain; Brain Ischemia; Cerebrovascular Circulation; Homeosta | 2005 |
Choice of antihypertensives after acute ischemic stroke.
Topics: Acute Disease; Antihypertensive Agents; Brain Ischemia; Drug Administration Schedule; Humans; Labeta | 2005 |
A comparison of nicardipine and labetalol for acute hypertension management following stroke.
Topics: Acute Disease; Aged; Antihypertensive Agents; APACHE; Blood Pressure; Brain Ischemia; Cerebral Hemor | 2008 |
Role of labetalol in acute myocardial infarction.
Topics: Acute Disease; Ethanolamines; Humans; Labetalol; Myocardial Infarction; Oxygen Consumption | 1982 |
Vasoactive mediators and the progression from oedematous to necrotising experimental acute pancreatitis.
Topics: Acute Disease; Animals; Arginine; Bradykinin; Catecholamines; Ceruletide; Edema; Labetalol; Male; Mi | 1995 |
Acute dissection of the thoracic aorta. Esmolol is safer than and as effective as labetalol.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aortic Aneurysm, Thoracic; Aortic Dissection; Humans; La | 1995 |
Acute secondary erythermalgia and hypertension in children. Erythermalgia Multidisciplinary Study Group.
Topics: Acute Disease; Adolescent; Alprostadil; Child; Child, Preschool; Erythromelalgia; Female; Humans; Hy | 1995 |
Acute hypertension promotes hemorrhagic transformation in a rabbit embolic stroke model: effect of labetalol.
Topics: Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Cerebral Hemorrhage; Cerebral Infar | 1998 |
Acute and chronic hypertensive headache and hypertensive encephalopathy.
Topics: Acute Disease; Antidepressive Agents; Antihypertensive Agents; Anxiety; Arterioles; Cerebral Arterie | 2002 |
Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension.
Topics: Acute Disease; Adult; Aged; Blood Pressure; Drug Administration Schedule; Drug Evaluation; Ethanolam | 1976 |
Labetalol and MRI as initial medical and diagnostic modalities in a marfanoid patient with expanding ascending aortic aneurysm.
Topics: Acute Disease; Aorta; Aortic Aneurysm; Aortic Dissection; Humans; Hypertension; Labetalol; Magnetic | 1990 |
Intravenous labetalol in acute aortic dissection.
Topics: Acute Disease; Aortic Aneurysm; Aortic Dissection; Humans; Infusions, Intravenous; Labetalol | 1987 |